RAP-536 was also shown to inhibit the overactivation of SMAD2/3 signaling, to improve anemia, and to decrease extramedullary erythropoiesis in a mouse model of β-thalassemia, also characterized by impaired erythroid maturation and ineffective erythropoiesis [28]. Here, SMAD2 is linked to anemia.